Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sonia Persaud"'
Autor:
Jenna Bhimani, Kelli O’Connell, Isaac J. Ergas, Marilyn Foley, Grace B. Gallagher, Jennifer J. Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H. Kroenke, Cecile. A. Laurent, Raymond Liu, Kanichi G. Nakata, Sonia Persaud, Donna R. Rivera, Janise M. Roh, Sara Tabatabai, Emily Valice, Erin J.A. Bowles, Elisa V. Bandera, Lawrence H. Kushi, Elizabeth D. Kantor
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-7 (2024)
Abstract Background Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal Breast Cancer Chemotherapy Dosing (OBCD) Stu
Externí odkaz:
https://doaj.org/article/e4df8f5cdae74a1a8836527359a19293
Autor:
Matthew K Chin, Lan N Đoàn, Rienna G Russo, Timothy Roberts, Sonia Persaud, Emily Huang, Lauren Fu, Kiran Y Kui, Simona C Kwon, Stella S Yi
Publikováno v:
Epidemiologic Reviews.
Improving race/ethnicity data quality is imperative to ensuring underserved populations are represented in datasets used to identify health disparities and inform healthcare policy. We performed a scoping review of methods that retrospectively improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89c83df5fe6a7b1ee4566547d4363ffe
https://doi.org/10.1093/epirev/mxad002
https://doi.org/10.1093/epirev/mxad002
Autor:
Jenna Bhimani, Kelli O’Connell, Rachael P. Burganowski, Isaac J. Ergas, Marilyn J. Foley, Grace B. Gallagher, Jennifer J. Griggs, Narre Heon, Tatjana Kolevska, Yuriy Kotsurovskyy, Candyce H. Kroenke, Kanichi G. Nakata, Sonia Persaud, Donna R. Rivera, Janise M. Roh, Sara Tabatabai, Emily Valice, Erin J. Bowles, Elisa V. Bandera, Lawrence H. Kushi, Elizabeth D. Kantor
Publikováno v:
Cancer Research. 83:P3-03
Introduction Chemotherapy administration in real-world cancer care can differ extensively from clinical trials. It is important to understand real-world practice to identify dose reductions, delays, regimen changes and early discontinuations that imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeea25a58419fc676791919a856fc291
https://doi.org/10.1158/1538-7445.sabcs22-p3-03-16
https://doi.org/10.1158/1538-7445.sabcs22-p3-03-16
Autor:
Aaron Philip Mitchell, Sonia Persaud, Susan Chimonas, Andrew L. Salner, Paul Palyca, Azeez Farooki, Jamie S. Ostroff, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 41:68-68
68 Background: NCCN Guidelines recommend the use of bone-modifying agents (BMAs) to prevent skeletal-related events (SRE) for patients with castrate-resistant prostate cancer (CRPC) and bone metastasis, but not for castrate-sensitive prostate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc6a8d65d7fc6de0e2cd3860e83f8441
https://doi.org/10.1200/jco.2023.41.6_suppl.68
https://doi.org/10.1200/jco.2023.41.6_suppl.68